China Junshi's potential COVID-19 drug shows promise in small trial - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.

  • 📰 SABCNews
  • ⏱ Reading Time:
  • 31 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 51%

ประเทศไทย ข่าว ข่าว

ประเทศไทย ข่าวล่าสุด,ประเทศไทย หัวข้อข่าว

An antiviral oral drug being co-developed by Shanghai Junshi Biosciences’ subsidiary and other Chinese institutes showed early promise in speeding the clearing of virus in COVID-19 patients…

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.

The drug, called VV116, is a derivative of Gilead SciencesInc’s COVID-19 drug remdesivir and was approved for use in moderate to severe cases in Uzbekistan last year. Participants were given either the five-day course oral drug along with standard treatment or standard treatment only, researchers said in a paper Emerging Microbes & Infections.

Limitations of the study include the small trial size and a higher portion of participants in the control group reporting symptoms, which could result in potential bias that researchers had to adjust with the statistical model, the paper said.

 

ขอบคุณสำหรับความคิดเห็นของคุณ ความคิดเห็นของคุณจะถูกเผยแพร่หลังจากได้รับการตรวจสอบแล้ว

A nother drug quickly made

I am super excited right now, I can now pay my bills and take good care of my family.. Thank you for bringing happiness to my home with just $5000 i got $50,000 in 7days Williamchurch07

Lmao

yup/// pfizer's pill is also reaylly successfull.. at killing people.. orally this time...

เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:

 /  🏆 37. in TH

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว